LY3561774 + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Dyslipidemias
Conditions
Dyslipidemias, Lipid Metabolism Disorders, Metabolic Diseases, Hyperlipoproteinemia
Trial Timeline
Jul 20, 2022 → May 23, 2024
NCT ID
NCT05256654About LY3561774 + Placebo
LY3561774 + Placebo is a phase 2 stage product being developed by Eli Lilly for Dyslipidemias. The current trial status is completed. This product is registered under clinical trial identifier NCT05256654. Target conditions include Dyslipidemias, Lipid Metabolism Disorders, Metabolic Diseases.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05256654 | Phase 2 | Completed |
| NCT04644809 | Phase 1 | Completed |
Competing Products
15 competing products in Dyslipidemias
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY3202328 + Placebo + Atorvastatin + Simvastatin | Eli Lilly | Phase 1 | 33 |
| Rosuampin 10/5mg + Rosuampin 20/5mg + Amlodipine/Atorvastatin 5/20mg | Yuhan | Approved | 85 |
| LY3475766 - IV + LY3475766 - SC + Placebo - IV + Placebo - SC | Eli Lilly | Phase 1 | 33 |
| LY3885125 + Placebo | Eli Lilly | Phase 1 | 33 |
| LY3561774 + Placebo | Eli Lilly | Phase 1 | 33 |
| LY2484595 + Placebo + Atorvastatin | Eli Lilly | Phase 2 | 52 |
| Atorvastatin + Atorvastatin | Pfizer | Approved | 84 |
| Atorvastatin | Pfizer | Approved | 84 |
| Atorvastatin + Atorvastatin + Atorvastatin | Pfizer | Approved | 84 |
| Vupanorsen + Placebo | Pfizer | Phase 2 | 51 |
| Atorvastatin | Pfizer | Approved | 84 |
| Atorvastatin + Atorvastatin + Atorvastatin | Pfizer | Approved | 84 |
| GWP42003 + GWP42003 + GWP42004 + Placebo | Jazz Pharmaceuticals | Phase 2 | 49 |
| ARO-APOC3 | Arrowhead Pharmaceuticals | Phase 2 | 49 |
| ARO-ANG3 + sterile normal saline (0.9% NaCl) | Arrowhead Pharmaceuticals | Phase 1 | 30 |